The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
· The study aims to confirm the safety and efficacy of pHyph in the treatment of vaginal yeast infection (VVC). · The study includes 26 patients, all of whom have now commenced treatment with pHyph. · Results from the study are expected in the second quarter of 2024. Lund, Sweden, February 8, 2024 The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of